Avastar

Avastar Therapeutics is a stealth-mode biotechnology company focused on the development of next-generation gene therapies using advanced AAV (adeno-associated virus) vector technology. Founded by gene therapy pioneer Dr. James M. Wilson and spun out from the University of Pennsylvania's Gene Therapy Program, the company utilizes its proprietary AvaStar platform to engineer novel AAV capsids with improved tissue specificity and reduced immunogenicity. As part of the G2 Bio Companies portfolio, Avastar aims to address a wide range of genetic and acquired diseases by optimizing the delivery and efficacy of genetic medicines. The company's research is centered on overcoming the current limitations of viral vectors to enable safer and more effective treatments for patients.